Key Stock Reports from Zacks Research (May 13, 2026)
The Zacks Research Daily highlights crucial findings on several major stocks: Meta Platforms, Inc. (META), Pfizer Inc. (PFE), and Salesforce, Inc. (CRM), based on 16 hand-picked research reports from a total of 70 released today. Meta’s shares have declined by 7.9% over the past year amidst rising AI infrastructure costs and scrutiny, while Pfizer’s stock has increased by 25.9%, benefiting from improved non-COVID operational revenues—even as it faces challenges from patent expirations. Salesforce, however, underperformed with a drop of 41.7%, impacted by stiff competition and currency fluctuations.
Meta is focusing on enhancing AI capabilities across its platforms, with increased infrastructure spending planned to support growth. Pfizer’s operational growth is attributed to key products like Vyndaqel and Eliquis, and it anticipates gradual recovery despite looming patent expirations. Meanwhile, Salesforce is leveraging digital transformation and strategic acquisitions to drive revenue growth despite competitive pressures.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
